SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics, Inc. (Nasdaq:MBRX), a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of metabolic and liver diseases by targeting the liver and liver pathways, announced today that it has initiated a Phase 1b clinical trial for MB07811, a novel, orally active product candidate for the management of hyperlipidemia. MB07811, Metabasis’ fifth internally discovered product candidate in clinical development, uses the Company’s proprietary HepDirect® prodrug technology to target a novel beta-subtype-selective thyroid hormone receptor (TRß) agonist to the liver to reduce serum cholesterol (LDL) and triglycerides (TGs).
